This company has been acquired
Y-mAbs Therapeutics Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Die Gewinne von Y-mAbs Therapeutics sind jährlich um durchschnittlich 29.4% gestiegen, während die Gewinne der Branche Biotechs jährlich um gewachsen um 33.8% gestiegen sind. Die Umsätze sind jährlich um gewachsen 32.2% gestiegen.
Wichtige Informationen
29.40%
Wachstumsrate der Gewinne
31.88%
EPS-Wachstumsrate
| Biotechs Wachstum der Industrie | 17.04% |
| Wachstumsrate der Einnahmen | 32.18% |
| Eigenkapitalrendite | -25.40% |
| Netto-Marge | -26.03% |
| Letzte Ertragsaktualisierung | 30 Jun 2025 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Y-mAbs Therapeutics: The Next Deal Showcases The Value And Challenges Of Biotech M&A
Summary Y-mAbs Therapeutics announced that it would be acquired at a >100% premium relative to recent trading. The deal showcases how little optimism there is in the biotech market at this time, even though recent investors are seeing substantial gains. This article lays out what SERB is going to get, and what I feel this transaction means for near-term biotech M&A. Read the full article on Seeking Alpha
Pipeline Developments And Radiopharmaceutical Advances Will Extend Global Reach
Despite improved profitability—with net profit margin rising to 12.26% and a lower future P/E of 47.56x—analysts have cut Y-mAbs Therapeutics’ consensus price target from $14.70 to $11.68, suggesting tempered growth expectations. What's in the News SERB S.A.S. agreed to acquire Y-mAbs Therapeutics for approximately $398.67 million ($8.6 per share); deal approved by Y-mAbs board and expected to close by December 31, 2025, subject to antitrust approval.Earnings Update: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
A week ago, Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) came out with a strong set of first-quarter numbers that could...Insufficient Growth At Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Hampers Share Price
Y-mAbs Therapeutics, Inc.'s ( NASDAQ:YMAB ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a strong...
DANYELZA And Radiopharmaceuticals Realignment Will Energize Global Opportunities
Strategic realignment into DANYELZA and Radiopharmaceuticals could enhance revenue growth and operational efficiency through focused business units.Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported And Analysts Have Been Cutting Their Estimates
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shareholders are probably feeling a little disappointed, since its shares...Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials
Summary YMAB's naxitamab sales declined from Q3 2023 to Q3 2024, but the company has a strong cash runway, supporting operations until 2027. Upcoming data readouts for GD2-SADA in Q2 2025 are critical for assessing the viability of their radiotherapy platform, most notably concerns related to toxicity. Despite risks, YMAB's current market cap of $270 million may be a bargain if upcoming data provides a clear clinical direction. I reiterate a "Buy" sentiment, with reservations about naxitamab sales growth and the uncertain future of GD2-SADA. Read the full article on Seeking AlphaBenign Growth For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Underpins Stock's 26% Plummet
To the annoyance of some shareholders, Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shares are down a considerable 26% in...We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26%
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shareholders that were waiting for something to happen have been dealt a blow...Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers
Summary Y-mAbs Therapeutics' naxitamab is approved for R/R High-Risk Neuroblastoma, with ongoing trials to expand its use, but the market size is limited. Financially, YMAB has a market cap of $644 million and a cash runway of 4-5 quarters, raising concerns about its ability to fund future R&D. The company is focusing on the SADA platform, but the lack of efficacy data makes it a speculative investment at this stage. Despite promising prospects, YMAB's low cash reserves and small market potential for naxitamab warrant a cautious investment approach. Read the full article on Seeking AlphaY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shares have had a really impressive month, gaining 33% after a shaky period...Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)
Summary YMAB maintains a market valuation around $500 million, potential for substantial appreciation. Pipeline updates include expanding the naxitamab market and progressing SADA radioimmunotherapeutic. Financially, YMAB has $77.8 million in cash, growing product revenues, and a cash runway of 8-9 quarters. Read the full article on Seeking AlphaWe're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%
The Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) share price has fared very poorly over the last month, falling by a...Y-mAbs: There's A Ceiling Here Somewhere
Summary Y-mAbs Therapeutics has experienced a significant recovery in value but lacks upcoming catalysts for near-term growth. Their approved therapy, naxitamab, has shown promising results in treating pediatric cancers. Y-mAbs' GD2-SADA pipeline project has potential but carries high risk, and the company's financials are stable for now. Read the full article on Seeking AlphaWe're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Y-mAbs...Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shares have continued their recent momentum with a 66% gain in the last month...Y-mAbs Therapeutics: A Monoclonal Antibody Play
Summary Y-mAbs Therapeutics' shares have rebounded massively since March 2023 due to the company's restructuring, extending its cash runway until 2027. The company's main commercial asset is Danyelza, a monoclonal antibody for the treatment of neuroblastoma, which has shown promising sales. Y-mAbs is also evaluating Danyelza for other indications and has a novel cancer treatment program called SADA, but these are still in early stages. Chase the rally or time to take some profits? A full investment analysis follows in the paragraphs below. Read the full article on Seeking AlphaWe're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Aufschlüsselung der Einnahmen und Ausgaben
Wie Y-mAbs Therapeutics Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Gewinn | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 25 | 85 | -22 | 45 | 43 |
| 31 Mar 25 | 89 | -28 | 51 | 45 |
| 31 Dec 24 | 88 | -30 | 50 | 47 |
| 30 Sep 24 | 85 | -24 | 50 | 49 |
| 30 Jun 24 | 87 | -25 | 51 | 54 |
| 31 Mar 24 | 84 | -22 | 45 | 53 |
| 31 Dec 23 | 85 | -21 | 45 | 50 |
| 30 Sep 23 | 93 | -19 | 44 | 56 |
| 30 Jun 23 | 85 | -39 | 48 | 62 |
| 31 Mar 23 | 75 | -74 | 50 | 76 |
| 31 Dec 22 | 65 | -96 | 52 | 89 |
| 30 Sep 22 | 43 | -134 | 57 | 98 |
| 30 Jun 22 | 40 | -135 | 57 | 99 |
| 31 Mar 22 | 40 | -117 | 58 | 92 |
| 31 Dec 21 | 35 | -55 | 57 | 91 |
| 30 Sep 21 | 46 | -38 | 56 | 86 |
| 30 Jun 21 | 37 | -42 | 54 | 84 |
| 31 Mar 21 | 26 | -60 | 50 | 95 |
| 31 Dec 20 | 21 | -119 | 46 | 93 |
| 30 Sep 20 | 0 | -123 | 38 | 86 |
| 30 Jun 20 | 0 | -114 | 31 | 85 |
| 31 Mar 20 | 0 | -91 | 24 | 69 |
| 31 Dec 19 | 0 | -81 | 20 | 63 |
| 30 Sep 19 | 0 | -72 | 16 | 57 |
| 30 Jun 19 | 0 | -59 | 14 | 47 |
| 31 Mar 19 | 0 | -52 | 12 | 40 |
| 31 Dec 18 | 0 | -43 | 9 | 34 |
| 30 Sep 18 | 0 | -38 | 9 | 30 |
| 30 Jun 18 | 0 | -31 | 7 | 24 |
| 31 Mar 18 | 0 | -24 | 5 | 18 |
| 31 Dec 17 | 0 | -19 | 5 | 14 |
Qualität der Erträge: YMAB ist derzeit unrentabel.
Wachsende Gewinnspanne: YMAB ist derzeit unrentabel.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: YMAB ist unrentabel, hat aber in den letzten 5 Jahren die Verluste mit einer Rate von 29.4% pro Jahr reduziert.
Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von YMAB verglichen werden, da das Unternehmen derzeit nicht profitabel ist.
Erträge im Vergleich zur Industrie: YMAB ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (43%) erschwert.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: YMAB hat eine negative Eigenkapitalrendite (-25.4%), da es derzeit unrentabel ist.
Kapitalrendite
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2025/09/15 02:06 |
| Aktienkurs zum Tagesende | 2025/09/15 00:00 |
| Gewinne | 2025/06/30 |
| Jährliche Einnahmen | 2024/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Y-mAbs Therapeutics, Inc. wird von 8 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Peter Lawson | Barclays |
| Yun Zhong | Brean Capital Historical (Janney Montgomery) |
| Thomas Shrader | BTIG |